PTC THERAPEUTICS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for PTC THERAPEUTICS, INC. (PTCT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PTCT insiders buying or selling?
In the last 12 months, PTC THERAPEUTICS, INC. insiders reported 0 open-market purchases ($0) and 70 sales ($57.9M) — net selling of $57.9M. Since January 2018, Trabud has recorded 294 Form 4 filings for PTCT: 3 buys ($2.5M) and 291 sells ($224.1M).
Source: SEC EDGAR Form 4
What stands out
- No PTC THERAPEUTICS, INC. insider made an open-market purchase in the last 12 months; the 70 reported open-market sales totaled $57.9M.
Key Statistics (January 2018 – Oct 16, 2026)
Total Form 4 filings
294
SEC EDGAR
Insider filers
20
Insider buys (3)
$2.5M
Insider sells (291)
$224.1M
Insider sentiment
Net sellingNet insider flow of $221.6M in net selling since January 2018, and $57.9M in net selling over the last 12 months.
Recent PTCT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Michael Schmertzler | Director | Sale | 2.5K | $59.61 | $149.0K | SEC ↗ |
| Oct 13, 2026 | Mark Elliott Boulding | EXEC. VP AND CLO | Sale | 192 | $64.26 | $12.3K | SEC ↗ |
| Oct 9, 2026 | Michael Schmertzler | Director | Sale | 2.5K | $63.39 | $158.5K | SEC ↗ |
| Oct 7, 2026 | Mark Elliott Boulding | EXEC. VP AND CLO | Sale | 2.1K | $64.06 | $132.8K | SEC ↗ |
| Oct 2, 2026 | Glenn Steele JR MD PHD | Director | Sale | 12.0K | $65.16 | $781.9K | SEC ↗ |
| Sep 18, 2026 | Michael Schmertzler | Director | Sale | 20.0K | $67.49 | $1.3M | SEC ↗ |
| Sep 11, 2026 | Michael Schmertzler | Director | Sale | 20.0K | $67.59 | $1.4M | SEC ↗ |
| Aug 28, 2026 | Michael Schmertzler | Director | Sale | 25.0K | $72.26 | $1.8M | SEC ↗ |
| Aug 21, 2026 | Michael Schmertzler | Director | Sale | 25.0K | $72.22 | $1.8M | SEC ↗ |
| Aug 19, 2026 | Mark Elliott Boulding | EXEC. VP AND CLO | Sale | 2.8K | $72.57 | $204.1K | SEC ↗ |
| Aug 6, 2026 | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Sale | 10.3K | $68.57 | $705.7K | SEC ↗ |
| Jul 16, 2026 | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale | 3.5K | $80.35 | $280.7K | SEC ↗ |
| Jul 13, 2026 | Mary L. Smith | Director | Sale | 15.8K | $90.00 | $1.4M | SEC ↗ |
| Jul 13, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | Sale | 2.5K | $90.25 | $222.4K | SEC ↗ |
| Jul 8, 2026 | Mark Elliott Boulding | EXEC. VP AND CLO | Sale | 5.1K | $85.08 | $432.1K | SEC ↗ |
| Jul 8, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | Sale | 46.8K | $87.52 | $4.1M | SEC ↗ |
| Jun 30, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | Sale | 8.1K | $85.26 | $693.2K | SEC ↗ |
| Jun 26, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | Sale | 26.3K | $85.78 | $2.3M | SEC ↗ |
| Jun 24, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | Sale | 23.7K | $80.90 | $1.9M | SEC ↗ |
| Jun 22, 2026 | Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | Sale | 19.7K | $75.56 | $1.5M | SEC ↗ |
| Jun 22, 2026 | Mark Elliott Boulding | EXEC. VP AND CLO | Sale | 10.5K | $78.65 | $822.9K | SEC ↗ |
| Jun 12, 2026 | Eric Pauwels | CHIEF BUSINESS OFFICER | Sale | 21.3K | $75.00 | $1.6M | SEC ↗ |
| May 19, 2026 | Mark Elliott Boulding | EXEC. VP AND CLO | Sale | 2.8K | $72.18 | $203.0K | SEC ↗ |
| May 15, 2026 | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Sale | 12.6K | $72.95 | $917.2K | SEC ↗ |
| May 12, 2026 | Mark Elliott Boulding | EXEC. VP AND CLO | Sale | 3.5K | $78.97 | $279.6K | SEC ↗ |
Showing the 25 most recent of 294 Form 4 filings for PTC THERAPEUTICS, INC..
Most active PTCT insiders
- Mark Elliott Boulding44 filings
- Neil Gregory Almstead39 filings
- Christine Marie Utter33 filings
- Eric Pauwels30 filings
- Stuart Walter Peltz29 filings
Ask anything about PTCT insider activity
Use Trabud's AI agent to query PTC THERAPEUTICS, INC.'s Form 4 history in plain English — "Show me PTCT CEO purchases this year" or compare it against any other ticker.
Open the AI agentPTCT insider trading FAQ
Are PTC THERAPEUTICS, INC. insiders buying or selling?
In the last 12 months, PTC THERAPEUTICS, INC. insiders reported 0 open-market purchases ($0) and 70 sales ($57.9M) — net selling of $57.9M. Since January 2018, Trabud has recorded 294 Form 4 filings for PTCT: 3 buys ($2.5M) and 291 sells ($224.1M). Over the full record that is net selling of $221.6M.
How many insiders trade PTCT stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for PTC THERAPEUTICS, INC.. The most recent filing was accepted on Oct 16, 2026.
Where does Trabud get PTCT insider trading data?
All PTCT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.